Chronic Spontaneous Urticaria — Stepwise Therapy

Key Points

• CSU is defined by spontaneous wheals, angioedema, or both recurring for more than six weeks.
• Individual wheals usually resolve within 24 hours without bruising.
• Broad allergy testing and food panels are not routinely useful for CSU.
• Daily second-generation H1 antihistamines are first-line therapy.
• Dose escalation up to fourfold is guideline-supported when standard dosing is inadequate.
• Omalizumab is the major next-line therapy for antihistamine-refractory CSU.
• Cyclosporine is a specialist option for severe refractory disease.
• Avoid chronic systemic corticosteroids because toxicity outweighs benefit.
• Measure control and quality-of-life impact, not just lesion count.

Algorithm

1. Confirm recurrent spontaneous wheals or angioedema lasting more than six weeks.
2. Exclude inducible urticaria, urticarial vasculitis, bradykinin angioedema, and systemic inflammatory mimics.
3. Perform limited baseline testing and add targeted tests only when history suggests another disorder.
4. Start a daily second-generation H1 antihistamine.
5. If control is inadequate, increase the antihistamine dose stepwise up to guideline-supported higher dosing.
6. If still uncontrolled, refer for omalizumab or other current biologic therapy.
7. For refractory severe disease, consider specialist-directed cyclosporine or newer options.
8. Avoid chronic steroids and reassess triggers, adherence, and diagnosis when control remains poor.

Clinical Synopsis & Reasoning

Chronic spontaneous urticaria, or CSU, is a mast-cell-driven disease characterized by recurrent itchy wheals, angioedema, or both on most days or intermittently for longer than six weeks without a reproducible specific external trigger. Individual wheals typically disappear within 24 hours without bruising. Angioedema can last longer. Chronic inducible urticarias, such as cold, cholinergic, pressure, or dermographism, should be separated because a physical stimulus can be demonstrated.

The diagnosis is clinical and broad screening panels are not recommended. History should assess lesion duration, angioedema, NSAID sensitivity, inducible triggers, infections or inflammatory symptoms, thyroid disease, medication exposures, and impact on sleep and function. Physical examination should look for dermographism and for features suggesting a different disorder. Painful fixed lesions lasting longer than 24 hours, residual bruising, fever, arthralgia, or abnormal systemic findings raise concern for urticarial vasculitis or autoinflammatory disease.

Food allergy is rarely the explanation for daily or near-daily CSU persisting for months. Extensive food panels often produce irrelevant sensitization results and unnecessary dietary restriction. Likewise, routine environmental allergy testing usually does not explain CSU. Limited baseline testing can include CBC and inflammatory markers, with thyroid or other testing guided by history and local guideline recommendations.

Disease activity and control should be measured because visible lesions underestimate the burden. Tools such as the Urticaria Activity Score and Urticaria Control Test help determine whether therapy is adequate. Angioedema frequency, sleep disruption, work or school impairment, and rescue-medication use are clinically meaningful outcomes.

Treatment Strategy & Disposition

Use a second-generation H1 antihistamine as first-line daily therapy rather than only as-needed treatment when symptoms are frequent. Modern urticaria guidelines prefer nonsedating or minimally sedating agents because first-generation antihistamines impair cognition, driving, sleep architecture, and work performance.

If a standard dose does not control disease, increase the dose of the same second-generation antihistamine, commonly up to fourfold under guideline-supported practice, before moving to more toxic chronic therapies. This is off-label for some agents and regions but is embedded in international urticaria guidance. Avoid mixing multiple sedating antihistamines as a substitute for rational dose escalation.

For persistent CSU despite high-dose second-generation antihistamine, omalizumab is the established next major step. Standard CSU dosing is commonly 300 mg subcutaneously every 4 weeks, with specialist-directed adjustment for incomplete response according to current guidelines and regulatory context. Newer biologic options are evolving, so long-term therapy should follow the most current allergy or dermatology guidance.

Cyclosporine is an effective specialist-directed option for severe omalizumab-refractory disease but requires monitoring for hypertension, kidney injury, drug interactions, and other toxicities. Chronic systemic corticosteroids should be avoided. A brief rescue course may occasionally be used for a severe flare, but repeated steroid bursts signal poor control and should trigger escalation of disease-modifying therapy.

Identify and minimize aggravating factors. NSAIDs worsen CSU in a subset of patients. Tight clothing, heat, alcohol, and stress can amplify symptoms for some individuals but are not universal causes. Treat confirmed inducible components separately and manage comorbid autoimmune thyroid disease when present, while avoiding unsupported infection or dietary eradication regimens.

Epidemiology / Risk Factors

• CSU affects both adults and children and can persist for months to years.
• Autoimmune mast-cell activation contributes to disease in a substantial subgroup.
• Angioedema occurs in many patients and can create significant anxiety even when it is not anaphylaxis.
• Quality-of-life impairment can be comparable to other chronic inflammatory diseases because of itch, sleep disruption, and unpredictability.
• Most patients eventually remit, but duration is highly variable.

Investigations

Therapy Ladder

Pharmacology

Prognosis / Complications

• Many patients achieve good control with antihistamines or omalizumab even before spontaneous remission occurs.
• Disease often fluctuates, so medication intensity can be reassessed periodically after sustained control.
• Frequent angioedema, high disease activity, and autoimmune features can be associated with a more persistent course.
• Chronic steroid exposure worsens long-term health and should not be accepted as routine maintenance.
• True progression from CSU to anaphylaxis is not the expected natural history, although patients can independently have anaphylactic allergies.

Patient Education / Counseling

• Explain that CSU is usually not caused by a hidden food and that restrictive diets rarely solve it.
• Take the second-generation antihistamine daily when disease is active rather than waiting until hives are severe.
• Avoid driving after sedating antihistamines and discuss switching to a second-generation agent.
• Keep photos and track symptoms or use a validated control score to help assess treatment response.
• Seek urgent care for breathing difficulty, fainting, or rapidly progressive throat symptoms because those suggest anaphylaxis or another airway problem.
• Ask for specialist escalation if repeated steroids are being used or high-dose antihistamine is not controlling symptoms.

Notes

The 2026 international urticaria guideline reinforces a treatment-to-control approach. The patient should not be left with daily disabling hives simply because a standard antihistamine dose failed. Dose escalation and biologic therapy allow many patients to reach near-complete control while avoiding chronic corticosteroid toxicity.

CSU also benefits from diagnostic restraint. Broad food allergy panels, parasite testing, and repeated infection screens rarely identify the cause in an otherwise typical case. Testing should be driven by findings that do not fit CSU, not by the frustration of having a chronic condition without a single external trigger.

References

1. International EAACI/GA2LEN/EuroGuiDerm/APAAACI Urticaria Guideline 2026 — Link
2. AAAAI Practice Parameters and Guidelines — Link